Replimune Group share price logo

Replimune Group

NASDAQ: REPL

Small Cap

$11.43

+0.38

(+3.44%)

as on

Replimune Group Stock Performance

as on October 21, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $10.99
    $11.69
    downward going graph

    3.85%

    Downside

    2.27%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $1.50
    $16.33
    downward going graph

    86.88%

    Downside

    42.87%

    Upside

    downward going graph

Replimune Group share price movements today

Previous Close
$11.05
Open
$10.99
Volume
853.0K
Market Cap
$1.0B
Day's Low - High
$10.99 - $11.69
52 Week Low - High
$1.50 - $16.33

Replimune Group Historical Returns

1 Month Return
-15.46 %
3 Month Return
+ 5.14 %
1 Year Return
+ 23.53 %
3 Year Return
-25.54 %
5 Year Return
-61.95 %

Replimune Group Stock Fundamentals & Key Indicators

Check Replimune Group market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$1.0B

EPS (TTM)

-3.15

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-3.45

Industry PE ratio

-7.03

PEG Ratio

-0.57

EBITDA

-287.2M

Revenue (TTM)

-

Profit Margin

0.00%

Return On Equity TTM

-159.32%

Replimune Group stock Key Stats

Compare market cap, revenue, PE, and other key metrics of Replimune Group with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
StrongBuy$1.0B-61.95%-3.450.00%0.00%

Stock Returns calculator for Replimune Group Stock including INR - Dollar returns

The Replimune Group stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

Replimune Group investment value today

Current value as on today

₹1,38,040

Returns

₹38,040

(+38.04%)

Returns from Replimune Group Stock

₹27,781 (+27.78%)

Dollar Impact

₹10,259 (+10.26%)

Analyst Recommendation on Replimune Group Stock

Based on 3 analysts

BUY

100.00%

Buy

0.00%

Hold

0.00%

Sell

Based on 3 analysts, 100% of analysts recommend a 'BUY' rating for Replimune Group. Average target price of $19.5

Replimune Group Share Price Target

Get share price movements and forecasts by analysts on Replimune Group.

What analysts predicted

41.38%UPSIDE

Target Price

$19.5

Current Price

$11.43

Analyzed by

3 Analysts

High

$21

Target

$19.50

Low

$14

Replimune Group target price $19.5, a slight upside of 41.38% compared to current price of $11.43. According to 3 analysts rating.

Indian Investors' Interest in Replimune Group Stock

Search interest for Replimune Group Stock has decreased by -33% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-33% versus previous 30 day period

Replimune Group Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
-
-
-
-
0
-
-
-
-
-
Operating Income
-58
-57
-58
-66
-79
-90
-84
-71
-73
-68
EBITDA
-57
-56
-57
-64
-71
-89
-81
-68
-70
-66
Interest Expense
1
1
1
1
1
1
0
1
4
2
Depreciation
0
0
0
0
0
0
0
0
1
1
Income Before Tax
-55
-53
-53
-65
-74
-86
-83
-71
-73
-69
Income Tax Expense
0
-
-
0
0
-
-
0
0
0
Net Income
-55
-53
-53
-66
-74
-86
-83
-70
-73
-69
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Replimune Group Annual Profit & Loss

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Total Revenue
-
-
-
-
-
-
-
-
-
-
Gross Profit
0
0
0
-
-4
-4
-
-
-
-
Operating Income
-9
-19
-30
-56
-82
-121
-177
-234
-261
-319
EBITDA
-8
-16
-30
-52
-78
-116
-171
-230
-256
-302
Interest Expense
-
-
-
1
3
2
4
6
7
8
Depreciation
0
0
0
0
1
2
2
2
3
3
Income Before Tax
-7
-19
-30
-52
-83
-121
-173
-215
-246
-314
Income Tax Expense
-
-
-
-
-2
-3
0
0
0
0
Net Income
-7
-19
-30
-52
-80
-118
-174
-215
-247
-313
Net Profit Margin
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%

Replimune Group Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-55
-53
-53
-66
-74
-86
-83
-70
-73
-69
Operating Cash Flow
-46
-49
-38
-50
-53
-77
-81
-65
-56
-75
Investing Cash Flow
23
29
0
-46
-7
65
84
75
86
49
Financing Cash Flow
0
96
0
155
0
0
0
10
55
0
Change in Cash
-23
77
-38
58
-61
-13
4
20
86
-23

Replimune Group Annual Cash Flow

All numbers in Millions USD

Mar 2017
Mar 2018
Mar 2019
Mar 2020
Mar 2021
Mar 2022
Mar 2023
Mar 2024
Mar 2025
Mar 2026
Net Income
-7
-19
-30
-52
-80
-118
-174
-215
-247
-313
Operating Cash Flow
-7
-16
-25
-60
-61
-82
-128
-185
-192
-280
Investing Cash Flow
0
-44
-65
-5
-188
-1
-142
97
-23
310
Financing Cash Flow
15
54
101
100
372
6
311
16
252
66
Change in Cash
6
-3
9
34
123
-76
40
-72
36
97

Global Institutional Holdings in Replimune Group

Check out the Institutions with significant holdings in Replimune Group.

Funds
Holdings
Felix Baker
11.72%
Vanguard
4.43%
iShares
4.31%
SPDR
3.08%
VANGUARD INDEX FUNDS
2.86%

Replimune Group News & Key Events

  • img

    Today's Timeline - 28 July

    Tue, 11:39 PM

    -

    FDA deems Replimune's IGNYTE study inadequate, leading to a significant stock drop.

    Wed, 04:08 AM

    -

    Replimune shares fall 38% after FDA documents raise doubts about cancer drug approval.

Insights on Replimune Group

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -13.38 Cr → 0.53 Cr (in ₹), with an average increase of 2624.5% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 6 months, REPL stock has moved up by 433.8%

  • imgNO EFFECT

    Promoter Holding Unchanged

    img

    Promoters holdings remained unchanged at 68.64% of holdings in Jun 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, eClerx Services Ltd has given 90.4% return, outperforming this stock by 163.3%

  • imgNO EFFECT

    Retail Holding Unchanged

    img

    Retail Investor holdings remained unchanged at 31.21% of holdings in Jun 2026 quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, One 97 Communications Ltd has given 29.1% return, outperforming this stock by 91.2%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 732.9% return, outperforming this stock by 709.4%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 182.2% return, outperforming this stock by 207.7%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 year, REPL stock has moved down by -62.1%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 4 quarters, 22.22 Cr → 10.28 Cr (in ₹), with an average decrease of 18.6% per quarter

About Replimune Group

Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
OrganisationReplimune Group
Headquarters500 Unicorn Park Drive, Woburn, MA, 01801, US
IndustryBiotechnology
CEOSushil Patel

Key Management of Replimune Group

Name

Title

Ms. Michelle DiNapoli

Chief Commercial Officer

Dr. Sushil Patel Ph.D.

CEO & Director

Ms. Emily Luisa Hill

Chief Financial Officer

Dr. Konstantinos Xynos M.B.A., M.D., Ph.D.

Chief Medical Officer

Mr. Philip Astley-Sparke F.S.A.

Executive Chairman

Ms. Carolyn Trott

Senior Vice President of Quality Assurance

Ms. Kari Jeschke

Senior Vice President of Regulatory Affairs

FAQs

What is Replimune Group share price today?

Replimune Group share price today is $11.43 as on at the close of the market. Replimune Group share today touched a day high of $11.69 and a low of $10.99.

What is the 52 week high and 52 week low for Replimune Group share?

Replimune Group share touched a 52 week high of $16.33 on and a 52 week low of $1.50 on . Replimune Group stock price today i.e. is closed at $11.43,which is 30.01% down from its 52 week high and 662.00% up from its 52 week low.

What is Replimune Group's market capitalisation today?

Replimune Group market capitalisation is $0.00T as on .

How to invest in Replimune Group Stock (REPL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Replimune Group on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Replimune Group Stock (REPL) from India?

Indian investors can start investing in Replimune Group (REPL) shares with as little as ₹94.93000030517578 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.30 in Replimune Group stock (as per the Rupee-Dollar exchange rate as on ). Based on Replimune Group share’s latest price of $11.43 as on October 21, 2026 at 1:29 am IST, you will get 0.8749 shares of Replimune Group. Learn more about fractional shares .

What are the returns that Replimune Group has given to Indian investors in the last 5 years?

Replimune Group stock has given -61.95% share price returns and 26.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?